Key Takeaways
- • Coherence Neuro, a Queensland-linked brain technology start-up co-founded by Australian electrical engineer Elise Jenkins, raised $65 million in a funding round led by Peter Thiel's Founders Fund and the OpenAI Startup Fund, according to the Australian Financial Review.
- • Founders Fund, which Peter Thiel describes as a $24 billion San Francisco venture capital firm, joined OpenAI's venture fund in backing the round.
- • The company is developing an implantable device intended to treat brain cancer and is currently in trials.
- • The OpenAI Startup Fund has previously invested in artificial intelligence start-ups, including Harvey AI.
Summary
Coherence Neuro, a start-up co-founded by Australian electrical engineer Elise Jenkins, has raised $65 million in a funding round led by Peter Thiel's Founders Fund and the OpenAI Startup Fund, according to the Australian Financial Review. The Queensland-linked company is trialling an implantable device designed to treat brain cancer, a field the Australian Financial Review frames under the headline "Zapping the cancer."
The article describes Founders Fund as a $24 billion San Francisco venture capital firm. It has joined the OpenAI Startup Fund, which has previously backed artificial intelligence companies including Harvey AI, in making what the publication describes as a major investment in the company.
The source article is partially behind a subscription paywall, so additional technical detail on the device, trial stage, and valuation was not available in the material reviewed.
The article describes Founders Fund as a $24 billion San Francisco venture capital firm. It has joined the OpenAI Startup Fund, which has previously backed artificial intelligence companies including Harvey AI, in making what the publication describes as a major investment in the company.
The source article is partially behind a subscription paywall, so additional technical detail on the device, trial stage, and valuation was not available in the material reviewed.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.